<DOC>
	<DOCNO>NCT02958982</DOCNO>
	<brief_summary>RP3128 calcium release activate calcium ( CRAC ) channel modulator . The purpose study evaluate safety , tolerability pharmacokinetics single multiple ascend dose ( ) RP3128 healthy volunteer evaluate effect late phase asthmatic response allergen challenge patient mild asthma .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Oral Doses RP3128 Rhizen Pharmaceuticals</brief_title>
	<detailed_description>The study consist three part ; Part 1 : single ascend dose ( SAD ) , Part 2 : multiple ascend dose ( MAD ) healthy volunteer Part 3 : proof concept ( POC ) study mild asthmatic . There 5 cohort SAD 3 cohort MAD , dose use MAD base emerge safety , tolerability pharmacokinetics ( PK ) Part 1 ( SAD ) . POC randomize , placebo- control , double blind , two period cross-over , proof concept study male female non child bear potential history mild asthma . high identify dose RP3128 Part 2 ( MAD ) consider POC</detailed_description>
	<criteria>Male nonchildbearing female subject ( SAD/MAD ) male nonchildbearing female patient mild asthma ; Healthy subject determine past medical history , vitals , physical examination 12lead ECG , clinical laboratory test . Body mass index ( BMI ) 18.0 30.0 kg/m2 inclusive , weight ≥50 kg ; Nonsmokers exsmokers Willingness adhere protocol requirement evidence informed consent form ( ICF ) duly read , sign date subject ; able comply protocol requirement study procedure ; Negative screen drug abuse alcohol screen admission . Male subject agree donate sperm 3 month post dose ; Female partner ( child bear potential ) male subject use 2 method highly effective contraception 3 month post last Additionally POC Pre bronchodilator Forced expiratory volume 1 sec ( FEV1 ) &gt; 70 % ( adjust age , sex race ) Steroid naïve subject history mild asthma satisfy Global Initiative Asthma ( GINA ) definition asthma , otherwise healthy . Subjects evidence history clinically significant medical history . History tuberculosis ( TB ) and/or positive Tuberculin Skin Test and/or QuantiFeron TB®Gold test . Use immunotherapy within 3 month prior screen . History serious adverse reaction , severe hypersensitivity allergy drug/drug substance ( except house dust mite , pollen allergen cat dander allergy asthmatic ) circumstance ( e.g . anaphylaxis ) ; Abnormal liver function Positive screen hepatitisB surface antigen ( HBsAg ) , antibodies hepatitis C ( HCV ) antibodies human immunodeficiency virus ( HIV ) 1,2 ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>RP3128</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>